Professor Lisa Butler

Lead SAiGENCI Associate

South Australian Immunogenomics Cancer Institute

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Professor Lisa Butler is a full-time academic researcher in the South Australian Immunogenomics Cancer Institute (SAiGENCI) and the Freemasons Centre for Male Health and Wellbeing (FCMHW) at the University of Adelaide, and is Director of the Solid Tumour Program at the South Australian Health and Medical Research Institute (SAHMRI). She holds key executive positions in the FCMHW, the Australian Prostate Cancer BioResource, the Prostate Cancer Foundation of Australia and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

My Research
Career
Publications
Grants and Funding
Teaching
Supervision
Professional Activities
Contact

Prof Butler has established an internationally-recognised research program focused on targeting androgen signalling in prostate cancer, discovering innovative biomarkers of response to treatment, and testing the efficacy of novel drugs for prostate cancer.

Prof Butler undertook postdoctoral studies at Memorial Sloan-Kettering Cancer Center in New York from 1998-2001. Her work there directly contributed to the clinical development of histone deacetylase inhibitors as anticancer agents and formed the basis of her interests in translational research. Since returning to Australia, a major focus of her research program has been the development of preclinical models that more closely represent the individual responses in men with prostate cancer. She developed the unique ex vivo tumor culture model, which has been applied to multiple tissues and resulted in the adoption of the technique by scientists from the University of Leuven, Belgium, Thomas Jefferson University, Philadelphia, UT Southwestern, Dallas and the Royal Marsden Hospital, London. Prof Butler’s research group has used this model to demonstrate the anti-proliferative efficacy of the novel heat shock protein 90 inhibitor AUY922 and the cyclin dependent kinase inhibitor ribociclib in prostate cancer tissues (Clin Cancer Res 18:3562), and funding was subsequently awarded by Cancer Australia in 2013 to translate these preclinical studies into an ongoing clinical trial of ribociclib for prostate cancer. From 2015-21 she led a Movember Revolutionary Team to investigate the role of lipids in prostate cancer and their potential for new biomarkers of disease aggressiveness, and in 2019 she and her collaborators were awarded funding from the US Department of Defense to further study the role of lipid metabolising enzymes in prostate cancer. Her other major research interests include development of novel combinatorial strategies to target the androgen receptor and lipid metabolism pathways in prostate cancer.

Appointments

Date	Position	Institution name
2022 - 2026	Head, Prostate Cancer Research Group	University of Adelaide
2022 - ongoing	Director, Solid Tumour Program	South Australian Health and Medical Research Institute
2018 - 2022	Cancer Council Principal Research Fellow	University of Adelaide
2014 - 2018	Australian Research Council Future Fellow	University of Adelaide
2012 - 2013	University Senior Research Fellow	University of Adelaide
2008 - 2012	Cancer Council SA Senior Research Fellow	University of Adelaide
2006 - 2008	Florey Research Fellow	University of Adelaide
2003 - 2005	Prostate Cancer Foundation of Australia Research Fellow	University of Adelaide
2002 - 2002	NHMRC Senior Research Officer	University of Adelaide
2001 - 2001	NHMRC Senior Research Officer	Flinders University

Awards and Achievements

Date	Type	Title	Institution Name	Country	Amount
2021	Award	Women in Leadership Award	Cancer Council SA Beat Cancer Project	Australia	$60,000
2011	Nomination	Nominated Delegate, NHMRC 75th Anniversary Symposium	National Health and Medical Research Council	Australia	-
2004	Honour	The Governor’s Leadership Foundation of South Australia	The Governor’s Leadership Foundation of South Australia	Australia	-
2003	Award	ILEX Oncology Scholar-in-Training Award	American Association for Cancer Research	United States	-
2002	Award	Bio-Rad New Investigator Award	Australian Society for Medical Research	Australia	-
2001	Award	Gerald B. Grindey Scholar In Training Award	American Association for Cancer Research	United States	-
1997	Award	AMRAD Young Investigator Award	Australian Society for Medical Research	Australia	-
1996	Award	The Ross Wishart Memorial Award	Australian Society for Medical Research	Australia	-
1994	Award	The R.F. Whelan Prize	The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists	Australia	-
1994	Award	Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Prize	The University of Adelaide	Australia	-

Education

Date	Institution name	Country	Title
1995 - 1998	University of Adelaide	Australia	PhD
1994 - 1994	University of Adelaide	Australia	BSC (Hons)
1991 - 1993	University of Adelaide	Australia	BSc

Postgraduate Training

Date Title Institution Country

1998 - 2001 Postdoctoral Fellow Memorial Sloan Kettering Cancer Center, New York United States
Research Interests

Cancer Cell Biology Cancer Therapy Cancer Biology and Clinical Oncology Nutrition and Metabolic Health Innovative Therapeutics Men's Health

Date	Title	Institution	Country
1998 - 2001	Postdoctoral Fellow	Memorial Sloan Kettering Cancer Center, New York	United States

Journals

Year	Citation
2024	Jiménez-Gracia, L., Marchese, D., Nieto, J. C., Caratù, G., Melón-Ardanaz, E., Gudiño, V., . . . Martelotto, L. G. (2024). FixNCut: single-cell genomics through reversible tissue fixation and dissociation. Genome Biology, 25(1), 81-1-81-36. DOI Scopus1 Europe PMC2
2024	Scott, J. S., Quek, L. E., Hoy, A. J., Swinnen, J. V., Nassar, Z. D., & Butler, L. M. (2024). Fatty acid elongation regulates mitochondrial β-oxidation and cell viability in prostate cancer by controlling malonyl-CoA levels. Biochemical and Biophysical Research Communications, 691, 7 pages. DOI
2024	Mah, C. Y., Nguyen, A. D. T., Niijima, T., Helm, M., Dehairs, J., Ryan, F. J., . . . Butler, L. M. (2024). Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer.. British Journal of Cancer, 130(5), 741-754. DOI Scopus2 Europe PMC2
2024	Truong, J. X. M., Rao, S. R., Ryan, F. J., Lynn, D. J., Snel, M. F., Butler, L. M., & Trim, P. J. (2024). Spatial MS multiomics on clinical prostate cancer tissues. Analytical and Bioanalytical Chemistry, 416(7), 1745-1757. DOI Scopus2 Europe PMC1
2024	Brennen, W. N., Le Magnen, C., Karkampouna, S., Anselmino, N., Bock, N., Choo, N., . . . Lawrence, M. G. (2024). Defining the challenges and opportunities for using patient-derived models in prostate cancer research. The Prostate, 84(7), 623-635. DOI
2024	Lin, H. M., Yang, X., Centenera, M. M., Huynh, K., Giles, C., Dehairs, J., . . . Horvath, L. G. (2024). Circulating Lipid Profiles Associated with Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer. JCO Precision Oncology, 8(8), 11 pages. DOI
2024	Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer. British Journal of Cancer, 131(6), 1092-1105. DOI
2024	Logan, J. M., Martini, C., Sorvina, A., Johnson, I. R. D., Brooks, R. D., Caruso, M. C., . . . Ung, B. S. -Y. (2024). Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers.. Scientific data, 11(1), 852. DOI Europe PMC1
2024	Nturubika, B. D., Guardia, C. M., Gershlick, D. C., Logan, J. M., Martini, C., Heatlie, J. K., . . . Johnson, I. R. D. (2024). Altered expression of vesicular trafficking machinery in prostate cancer affects lysosomal dynamics and provides insight into the underlying biology and disease progression. British Journal of Cancer, 131(8), 1263-1278. DOI
2024	Sardar, S., McNair, C. M., Ravindranath, L., Chand, S. N., Yuan, W., Bogdan, D., . . . Shafi, A. A. (2024). AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer. Oncogene, 43(43), 17 pages. DOI
2024	Wang, T., Roach, M. J., Harvey, K., Morlanes, J. E., Kiedik, B., Al-Eryani, G., . . . Martelotto, L. G. (2024). snPATHO-seq, a versatile FFPE single-nucleus RNA sequencing method to unlock pathology archives. Communications Biology, 7(1), 1340. DOI
2024	Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.. Br J Cancer. DOI
2024	Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis. Cancer Research, 84(14), 2313-2332. DOI Europe PMC1
2024	Sardar, S., McNair, C. M., Ravindranath, L., Chand, S. N., Yuan, W., Bogdan, D., . . . Shafi, A. A. (2024). AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.. bioRxiv. DOI
2024	Boufaied, N., Chetta, P., Hallal, T., Cacciatore, S., Lalli, D., Luthold, C., . . . Zadra, G. (2024). Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer. Cancer Research, 84(11), 1834-1855. DOI Scopus2
2024	Cilento, M. A., Sweeney, C. J., & Butler, L. M. (2024). Spatial transcriptomics in cancer research and potential clinical impact: a narrative review. Journal of Cancer Research and Clinical Oncology, 150(6), 296-1-296-16. DOI
2023	Martini, C., Logan, J. M., Sorvina, A., Gordon, C., Beck, A. R., S-Y Ung, B., . . . Brooks, D. A. (2023). Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer. Pathology, 55(1), 40-51. DOI Scopus14 WoS8 Europe PMC12
2023	Shin, S. Y., Centenera, M. M., Hodgson, J. T., Nguyen, E. V., Butler, L. M., Daly, R. J., & Nguyen, L. K. (2023). A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer. Frontiers in Molecular Biosciences, 10, 1094321-1-1094321-16. DOI Scopus4 WoS1 Europe PMC1
2023	Scheinberg, T., Mak, B., Butler, L., Selth, L., & Horvath, L. G. (2023). Targeting lipid metabolism in metastatic prostate cancer. Therapeutic Advances in Medical Oncology, 15, 1-30. DOI Scopus14 WoS1 Europe PMC11
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S2 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. DOI
2023	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S1 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. DOI
2023	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Supplementary Figures and Legends 1-8 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. DOI
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S2 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. DOI
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Data from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. DOI
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Data from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S1 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. DOI
2023	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S3 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. DOI
2023	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S3 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. DOI
2023	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Data from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. DOI
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S4 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. DOI
2023	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S4 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. DOI
2023	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. DOI
2023	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Supplementary Figures and Legends 1-8 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. DOI
2023	Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. DOI
2023	Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Supplementary Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. DOI
2023	Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Supplementary Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. DOI
2023	Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (2023). Data from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. DOI
2023	Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (2023). Supplementary Figures 1-3 from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. DOI
2023	Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (2023). Supplementary Figures 1-3 from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer. DOI
2023	Logan, J. M., Hopkins, A. M., Martini, C., Sorvina, A., Tewari, P., Prabhakaran, S., . . . Brooks, D. A. (2023). Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1.. Cancers, 15(12), 1-12. DOI Scopus8 WoS2 Europe PMC3
2023	Menzel, J. P., Young, R. S. E., Benfield, A. H., Scott, J. S., Wongsomboon, P., Cudlman, L., . . . Blanksby, S. J. (2023). Ozone-enabled fatty acid discovery reveals unexpected diversity in the human lipidome. Nature Communications, 14(1), 1-16. DOI Scopus20 WoS3 Europe PMC6
2023	Butler, L. M., & Evergren, E. (2023). Ultrastructural analysis of prostate cancer tissue provides insights into androgen-dependent adaptations to membrane contact site establishment. Frontiers in Oncology, 13, 1217741-1-1217741-13. DOI Scopus2 Europe PMC1
2023	Lazniewska, J., Li, K. L., Johnson, I. R. D., Sorvina, A., Logan, J. M., Martini, C., . . . Brooks, D. A. (2023). Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression. Scientific reports, 13(1), 1-18. DOI Scopus4 Europe PMC3
2023	Hinneh, J. A., Gillis, J. L., Mah, C. Y., Irani, S., Shrestha, R. K., Ryan, N. K., . . . Butler, L. M. (2023). Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer. British Journal of Cancer, 129(8), 1350-1361. DOI Scopus4 Europe PMC1
2022	A, M., Owen, K. L., Townley, S., Zanker, D., Rollin, S. P. G., Hanson, A. R., . . . Selth, L. A. (2022). Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer. Cancer research communications, 2(7), 706-724. DOI Scopus7 WoS1 Europe PMC4
2022	Scott, J. S., Nassar, Z. D., Swinnen, J. V., & Butler, L. M. (2022). Monounsaturated fatty acids: key regulators of cell viability and intracellular signalling in cancer.. Mol Cancer Res, 20(9), 1354-1364. DOI Scopus13 WoS8 Europe PMC12
2022	Linder, S., Hoogstraat, M., Stelloo, S., Eickhoff, N., Schuurman, K., de Barros, H., . . . Zwart, W. (2022). Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence.. Cancer discovery, 12(9), 2074-2097. DOI Scopus30 WoS9 Europe PMC24
2022	Hinneh, J. A., Gillis, J. L., Moore, N. L., Butler, L. M., & Centenera, M. M. (2022). The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilities. Frontiers in Oncology, 12, 1-14. DOI Scopus14 WoS3 Europe PMC9
2022	Kobayashi, H., Gieniec, K. A., Lannagan, T. R., Wang, T., Asai, N., Mizutani, Y., . . . Worthley, D. L. (2022). The origin and contribution of cancer-associated fibroblasts in colorectal carcinogenesis. Gastroenterology, 162(3), 890-906. DOI Scopus83 WoS37 Europe PMC67
2022	Raftopulos, N. L., Washaya, T. C., Niederprum, A., Egert, A., Hakeem-Sanni, M. F., Varney, B., . . . Hoy, A. J. (2022). Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover. Cancer & Metabolism, 10(1), 1-15. DOI WoS13 Europe PMC16
2022	Dylgjeri, E., Kothari, V., Shafi, A. A., Semenova, G., Gallagher, P. T., Guan, Y. F., . . . Knudsen, K. E. (2022). A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration Resistant Prostate Cancer. Clinical Cancer Research, 28(7), 1446-1459. DOI Scopus14 WoS8 Europe PMC12
2022	Mak, B., Lin, H. -M., Kwan, E. M., Fettke, H., Tran, B., Davis, I. D., . . . Horvath, L. G. (2022). Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Medicine, 20(1), 112-1-112-14. DOI Scopus10 WoS9 Europe PMC10
2022	Mutuku, S. M., Spotbeen, X., Trim, P. J., Snel, M. F., Butler, L. M., & Swinnen, J. V. (2022). Unravelling Prostate Cancer Heterogeneity Using Spatial Approaches to Lipidomics and Transcriptomics. Cancers, 14(7), 1-16. DOI Scopus11 WoS4 Europe PMC8
2022	Centenera, M. M., Vincent, A. D., Moldovan, M., Lin, H. M., Lynn, D. J., Horvath, L. G., & Butler, L. M. (2022). Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants. Cancers, 14(7), 1-18. DOI Scopus10 WoS2 Europe PMC7
2022	Mak, B., Lin, H. -M., Duong, T., Mahon, K. L., Joshua, A. M., Stockler, M. R., . . . Horvath, L. G. (2022). Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin. Cancers, 14(19), 1-15. DOI Scopus5 WoS3 Europe PMC3
2022	Menzel, J. P., Young, R. S. E., Benfield, A. H., Scott, J., Butler, L. M., Henriques, S. T., . . . Blanksby, S. J. (2022). OzFAD: Ozone-enabled fatty acid discovery reveals unexpected diversity in the human lipidome. DOI
2021	Allen, J. A., Butler, L., Levine, T., & Haudrich, A. (2021). A Global Survey of Disease Burden in Patients Who Carry a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy. ADVANCES IN THERAPY, 38(1), 316-328. DOI WoS7
2021	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S., . . . Swinnen, J. V. (2021). Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Research. DOI
2021	Lin, H. M., Mak, B., Yeung, N., Huynh, K., Meikle, T. G., Mellett, N. A., . . . Horvath, L. G. (2021). Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine, 72, 103625-1-103625-15. DOI Scopus26 WoS19 Europe PMC20
2021	Tieu, T., Irani, S., Bremert, K. L., Ryan, N. K., Wojnilowicz, M., Helm, M., . . . Cifuentes-Rius, A. (2021). Patient-derived prostate cancer explants: a clinically relevant model to assess siRNA-based nanomedicines. Advanced Healthcare Materials, 10(6), 2001594-1-2001594-11. DOI Scopus12 WoS9 Europe PMC6
2021	Kwan, K. H., Burvenich, I. J. G., Centenera, M. M., Goh, Y. W., Rigopoulos, A., Dehairs, J., . . . Ackermann, U. (2021). Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. Nuclear medicine and biology, 93, 37-45. DOI Scopus3 WoS3 Europe PMC1
2021	Lin, H. -M., Huynh, K., Kohli, M., Tan, W., Azad, A. A., Yeung, N., . . . Horvath, L. G. (2021). Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 24(3), 860-870. DOI Scopus16 WoS12 Europe PMC13
2021	Gillis, J. L., Hinneh, J. A., Ryan, N. K., Irani, S., Moldovan, M., Quek, L. -E., . . . Butler, L. M. (2021). A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth. eLife, 10, e62592-1-e62592-27. DOI Scopus19 WoS12 Europe PMC15
2021	Hoy, A. J., Nagarajan, S. R., & Butler, L. M. (2021). Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nature Reviews Cancer, 21(12), 753-766. DOI Scopus185 WoS134 Europe PMC143
2021	Fernandes, R. C., Toubia, J., Townley, S., Hanson, A. R., Dredge, B. K., Pillman, K. A., . . . Selth, L. A. (2021). Post-transcriptional gene regulation by microRNA-194 promotes neuroendocrine transdifferentiation in prostate cancer. Cell Reports, 34(1), 1-17. DOI Scopus30 WoS23 Europe PMC24
2021	Nagarajan, S. R., Butler, L. M., & Hoy, A. J. (2021). The diversity and breadth of cancer cell fatty acid metabolism. Cancer & Metabolism, 9(1), 1-28. DOI WoS84 Europe PMC77
2021	Kokkinos, J., Sharbeen, G., Haghighi, K. S., Ignacio, R. M. C., Kopecky, C., Gonzales-Aloy, E., . . . Phillips, P. A. (2021). Ex vivo culture of intact human patient derived pancreatic tumour tissue. Scientific Reports, 11(1), 1-15. DOI Scopus38 WoS20 Europe PMC18
2021	Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S., . . . Swinnen, J. V. (2021). Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Research, 81(19), 4981-4993. DOI Scopus45 WoS26 Europe PMC36
2021	Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2021). ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. Cancer Research, 81(7), 1704-1718. DOI Scopus50 WoS36 Europe PMC37
2021	Truong, J. X. M., Spotbeen, X., White, J., Swinnen, J. V., Butler, L. M., Snel, M. F., & Trim, P. J. (2021). Removal of optimal cutting temperature (O.C.T.) compound from embedded tissue for MALDI imaging of lipids.. Anal Bioanal Chem, 413(10), 2695-2708. DOI Scopus21 WoS13 Europe PMC14
2020	Kobayashi, H., Gieniec, K. A., Wright, J. A., Wang, T., Asai, N., Mizutani, Y., . . . Woods, S. L. (2020). The Balance of stromal BMP signaling mediated by GREM1 and ISLR drives colorectal carcinogenesis. Gastroenterology, 160(4), 1224-1239. DOI Scopus85 WoS60 Europe PMC72
2020	Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2020). Fatty acid oxidation is an adaptive survival pathway induced in prostate tumors by heat shock protein 90 inhibition. Molecular cancer research : MCR, 18(10), 1500-1511. DOI Scopus16 WoS10 Europe PMC10
2020	Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J., Irani, S., Centenera, M. M., . . . Butler, L. M. (2020). Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. Elife, 9, 1-34. DOI Scopus107 WoS70 Europe PMC70
2020	Butler, L., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., . . . Swinnen, J. V. (2020). Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.. Advanced drug delivery reviews, 159, 245-293. DOI Scopus347 WoS253 Europe PMC239
2020	Hollis, B., Day, F. R., Busch, A. S., Thompson, D. J., Soares, A. L. G., Timmers, P. R. H. J., . . . Butler, L. (2020). Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan. Nature Communications, 11(1), 1536-1-1536-10. DOI Scopus38 Europe PMC24
2020	Wu, Y., Xie, J., Xin, J., Lenchine, R. V., Wang, X., Fang, M. D., . . . Proud, C. G. (2020). eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA. Biochemical Journal, 477(22), 4367-4381. DOI Scopus25 WoS22 Europe PMC19
2020	Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., Sebastian, L., Stricker, P., . . . Horvath, L. G. (2020). Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). BMJ Open, 10(1), e033667-1-e033667-6. DOI Scopus13 WoS12 Europe PMC10
2020	Jankovic-Karasoulos, T., Bianco-Miotto, T., Butler, M. S., Butler, L. M., McNeil, C. M., O'Toole, S. A., . . . Ricciardelli, C. (2020). Elevated levels of tumor apolipoprotein D independently predict poor outcome in breast cancer patients. Histopathology, 76(7), 976-987. DOI Scopus20 WoS11 Europe PMC13
2020	Mah, C. Y., Nassar, Z. D., Swinnen, J. V., & Butler, L. M. (2020). Lipogenic effects of androgen signaling in normal and malignant prostate. Asian Journal of Urology, 7(3), 258-270. DOI Scopus24 WoS18 Europe PMC15
2020	Xie, J., Shen, K., Jones, A. T., Yang, J., Tee, A. R., Shen, M. H., . . . Proud, C. G. (2020). Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.. Cellular and molecular life sciences : CMLS, 78(1), 249-270. DOI Scopus15 WoS13 Europe PMC9
2020	Owen, K. L., Gearing, L. J., Zanker, D. J., Brockwell, N. K., Khoo, W. H., Roden, D. L., . . . Parker, B. S. (2020). Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Reports, 21(6), e50162-1-e50162-24. DOI Scopus60 WoS49 Europe PMC51
2020	Shirazi, H. S., Chan, K. M., Rouget, J., Ostrikov, K., McNicholas, K., Li, J., . . . MacGregor, M. (2020). Plasma enabled devices for the selective capture and photodynamic identification of prostate cancer cells.. Biointerphases, 15(3), 031002. DOI Scopus10 WoS9 Europe PMC4
2020	Miladinovic, D., Cusick, T., Mahon, K. L., Haynes, A. -M., Cortie, C. H., Meyer, B. J., . . . Hoy, A. J. (2020). Assessment of Periprostatic and Subcutaneous Adipose Tissue Lipolysis and Adipocyte Size from Men with Localized Prostate Cancer. Cancers, 12(6), 1385-1-1385-19. DOI Scopus14 WoS10 Europe PMC10
2020	Zadra, G., Ribeiro, C. F., Chetta, P., Cacciatore, S., Gao, X., Syamala, S., . . . Loda, M. (2020). Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer (vol 116, pg 631, 2018). PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 117(31), 18893. DOI
2019	Johnson, I. R. D., Sorvina, A., Logan, J. M., Moore, C. R., Heatlie, J. K., Parkinson-Lawrence, E. J., . . . Brooks, D. A. (2019). A paradigm in immunochemistry, revealed by monoclonal antibodies to spatially distinct epitopes on Syntenin-1. International Journal of Molecular Sciences, 20(23), 6035-1-6035-16. DOI Scopus5 WoS4 Europe PMC3
2019	Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J. G., Irani, S., Centenera, M. M., . . . Butler, L. M. (2019). DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. DOI
2019	Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (2019). Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer. Molecular Cancer Research, 17(4), 949-962. DOI Scopus60 WoS53 Europe PMC43
2019	Zadra, G., Ribeiro, C. F., Chetta, P., Ho, Y., Cacciatore, S., Gao, X., . . . Loda, M. (2019). Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 116(2), 631-640. DOI Scopus189 WoS154 Europe PMC150
2019	Matejcic, M., Saunders, E. J., Dadaev, T., Brook, M. N., Wang, K., Sheng, X., . . . Ranu, H. (2019). Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1). Nature Communications, 10(1), 5 pages. DOI Scopus1 WoS1 Europe PMC2
2019	Zhang, A. Y., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. G. (2019). An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. International Journal of Cancer, 144(5), 1151-1159. DOI Scopus12 WoS11 Europe PMC7
2019	Mutuku, S. M., Trim, P. J., Prabhala, B. K., Irani, S., Bremert, K. L., Logan, J. M., . . . Butler, L. M. (2019). Evaluation of small molecule drug uptake in patient-derived prostate cancer explants by mass spectrometry. Scientific Reports, 9(1), 15008. DOI Scopus13 WoS9 Europe PMC9
2019	Irani, Y. D., Pulford, E., Mortimer, L., Irani, S., Butler, L., Klebe, S., & Williams, K. A. (2019). Sex differences in corneal neovascularization in response to superficial corneal cautery in the rat. PLoS ONE, 14(9), e0221566-1-e0221566-17. DOI Scopus6 WoS4 Europe PMC4
2019	Tieu, T., Dhawan, S., Haridas, V., Butler, L. M., Thissen, H., Cifuentes-Rius, A., & Voelcker, N. H. (2019). Maximizing RNA loading for gene silencing using porous silicon nanoparticles. ACS Applied Materials and Interfaces, 11(26), 22993-23005. DOI Scopus27 WoS18 Europe PMC4
2019	Gieniec, K. A., Butler, L. M., Worthley, D. L., & Woods, S. L. (2019). Cancer-associated fibroblasts—heroes or villains?. British Journal of Cancer, 121(4), 293-302. DOI Scopus163 WoS127 Europe PMC118
2018	McClurg, U. L., McCracken, S. R., Butler, L., Riabowol, K. T., & Binda, O. (2018). Ex vivo culture and lentiviral transduction of Benign Prostatic Hyperplasia (BPH) samples. Bio-protocols, 8(21), e3075-. DOI WoS2 Europe PMC1
2018	Matejcic, M., Saunders, E. J., Dadaev, T., Brook, M. N., Wang, K., Sheng, X., . . . Butler, L. (2018). Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 9(1), 4616-1-4616-11. DOI Scopus43 WoS34 Europe PMC38
2018	Nguyen, E., Centenera, M., Moldovan, M., Das, R., Irani, S., Vincent, A., . . . Butler, L. (2018). Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants. Molecular & cellular proteomics : MCP, 17(8), 1470-1486. DOI Scopus27 WoS25 Europe PMC19
2018	Dadaev, T., Saunders, E., Newcombe, P., Anokian, E., Leongamornlert, D., Brook, M., . . . Sellers, T. (2018). Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 9(1), 19 pages. DOI Scopus76 WoS65 Europe PMC70
2018	Aref, A., Vincent, A. D., O'Callaghan, M., Martin, S., Sutherland, P., Hoy, A., . . . Wittert, G. (2018). The inverse relationship between prostate specific antigen (PSA) and obesity. Endocrine-Related Cancer, 25(11), 933-941. DOI Scopus19 WoS13 Europe PMC12
2018	Shafi, A., Schiewer, M., de Leeuw, R., Dlygeri, E., McCue, P., Shah, N., . . . Knudsen, K. (2018). Novel patient derived models reveal the impact of the tumor microenvironment on therapeutic response. European Urology Oncology, 1(4), 325-337. DOI Scopus38 WoS34 Europe PMC33
2018	Centenera, M. M., Hickey, T. E., Jindal, S., Ryan, N. K., Ravindranathan, P., Mohammed, H., . . . Tilley, W. D. (2018). A patient-derived explant (PDE) model of hormone-dependent cancer. Molecular Oncology, 12(9), 1608-1622. DOI Scopus89 WoS65 Europe PMC67
2018	Su, Y. W., Chim, S. M., Zhou, L., Hassanshahi, M., Chung, R., Fan, C., . . . Xian, C. J. (2018). Osteoblast derived-neurotrophin‑3 induces cartilage removal proteases and osteoclast-mediated function at injured growth plate in rats. Bone, 116, 232-247. DOI Scopus17 WoS13 Europe PMC7
2018	Lin, H., Lee, B., Castillo, L., Spielman, C., Grogan, J., Yeung, N., . . . Daly, R. (2018). Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. The Prostate, 78(4), 308-317. DOI Scopus49 WoS43 Europe PMC32
2018	Armstrong, H., Gillis, J., Johnson, I., Nassar, Z., Moldovan, M., Levrier, C., . . . Butler, L. (2018). Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. Scientific reports, 8(1), 2090-1-2090-14. DOI Scopus31 WoS26 Europe PMC23
2018	McClurg, U., Nabbi, A., Ricordel, C., Korolchuk, S., McCracken, S., Heer, R., . . . Binda, O. (2018). Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein. British journal of cancer, 118(5), 713-726. DOI Scopus24 WoS24 Europe PMC17
2018	Nassar, Z., Aref, A., Miladinovic, D., Mah, C., Raj, G., Hoy, A., & Butler, L. (2018). Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer. BJU International, 121(Suppl. 3), 9-21. DOI Scopus60 WoS51 Europe PMC42
2018	Cifuentes-Rius, A., Butler, L., & Voelcker, N. (2018). Precision nanomedicines for prostate cancer. Nanomedicine, 13(8), 803-807. DOI Scopus7 WoS6 Europe PMC3
2018	Ricciardelli, C., Bianco-Miotto, T., Jindal, S., Butler, L., Leung, S., McNeil, C., . . . Tilley, W. (2018). The magnitude of androgen receptor positivity in breast cancer is critical for reliable prediction of disease outcome. Clinical Cancer Research, 24(10), 2328-2341. DOI Scopus65 WoS53 Europe PMC51
2018	Centenera, M., Selth, L., Ebrahimie, E., Butler, L., & Tilley, W. (2018). New opportunities for targeting the androgen receptor in prostate cancer. Cold Spring Harbor Perspectives in Medicine, 10(12), 1-19. DOI Scopus22 WoS18 Europe PMC15
2017	Das, R., Gregory, P. A., Fernandes, R. C., Denis, I., Wang, Q., Townley, S. L., . . . Selth, L. A. (2017). MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Research, 77(4), 1021-1034. DOI Scopus97 WoS88 Europe PMC67
2017	Tran, L. N., Kichenadasse, G., Butler, L. M., Centenera, M. M., Morel, K. L., Ormsby, R. J., . . . Sykes, P. J. (2017). The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer. Molecular cancer therapeutics, 16(12), 2689-2700. DOI Scopus26 WoS22 Europe PMC14
2017	Selth, L., Das, R., Townley, S., Coutinho, I., Hanson, A., Centenera, M., . . . Tilley, W. (2017). A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene, 36(1), 24-34. DOI Scopus91 WoS84 Europe PMC61
2016	Xie, J., Mølck, C., Paquet-Fifield, S., Butler, L., Sloan, E., Ventura, S., & Hollande, F. (2016). High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgenindependent prostate cancer cells. Oncotarget, 7(28), 44492-44504. DOI Scopus17 WoS12 Europe PMC10
2016	Philp, L., Day, T., Butler, M., Laven-Law, G., Jindal, S., Hickey, T., . . . Tilley, W. (2016). Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) ablation limits offspring viability and growth in mice. Scientific Reports, 6(1), 28950-1-28950-14. DOI Scopus8 WoS8 Europe PMC7
2016	Armstrong, H., Koay, Y., Irani, S., Das, R., Nassar, Z., The Australian Prostate Cancer BioResource., . . . Butler, L. (2016). A novel class of Hsp90 C-terminal modulators have pre-clinical efficacy in prostate tumor cells without induction of a heat shock response. Prostate, 76(16), 1546-1559. DOI Scopus21 WoS21 Europe PMC15
2016	Butler, L., Centenera, M., & Swinnen, J. (2016). Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. Endocrine-Related Cancer, 23(5), 219-227. DOI Scopus95 WoS75 Europe PMC67
2016	Carter, S., Centenera, M., Tilley, W., Selth, L., & Butler, L. (2016). IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer, 16(1), 141-1-141-13. DOI Scopus12 WoS11 Europe PMC7
2016	Carter, S. L., Centenera, M. M., Tilley, W. D., Selth, L. A., & Butler, L. M. (2016). Erratum to: IΚBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.[BMC Cancer. 2016] 16:141. Doi: 10.1186/s12885-016-2188-2.. BMC Cancer, 16(1), 1 page. DOI Europe PMC1
2015	Johnson, I., Parkinson-Lawrence, E., Keegan, H., Spillane, C., Barry-O'Crowley, J., Watson, W., . . . Brooks, D. (2015). Endosomal gene expression: a new indicator for prostate cancer patient prognosis?. Oncotarget, 6(35), 37919-37929. DOI Scopus35 WoS28 Europe PMC30
2015	Centenera, M., Carter, S., Gillis, J., Marrocco-Tallarigo, D., Grose, R., Tilley, W., & Butler, L. (2015). Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Endocrine-Related Cancer, 22(5), 805-818. DOI Scopus24 WoS23 Europe PMC18
2015	Butler, L., Ferraldeschi, R., Armstrong, H., Centenera, M., & Workman, P. (2015). Maximizing the therapeutic potential of HSP90 inhibitors. Molecular Cancer Research, 13(11), 1445-1451. DOI Scopus153 WoS140 Europe PMC118
2014	Johnson, I., Parkinson-Lawrence, E., Butler, L., & Brooks, D. (2014). Prostate cell lines as models for biomarker discovery: performance of current markers and the search for new biomarkers. Prostate, 74(5), 547-560. DOI Scopus19 WoS15 Europe PMC13
2014	Johnson, I., Parkinson-Lawrence, E., Shandala, T., Weigert, R., Butler, L., & Brooks, D. (2014). Altered endosome biogenesis in prostate cancer has biomarker potential. Molecular Cancer Research, 12(12), 1851-1862. DOI Scopus37 WoS23 Europe PMC26
2014	Selth, L. A., Roberts, M. J., Chow, C. W. K., Marshall, V. R., Doi, S. A. R., Vincent, A. D., . . . Gardiner, R. A. (2014). Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocrine-Related Cancer, 21(4), L17-L21. DOI Scopus35 WoS30 Europe PMC28
2014	Tarulli, G. A., Butler, L. M., Tilley, W. D., & Hickey, T. E. (2014). Bringing androgens up a NOTCH in breast cancer. Endocrine-Related Cancer, 21(4), T183-T202. DOI Scopus25 WoS24 Europe PMC19
2014	Ochnik, A., Moore, N., Jankovic-Karasoulos, T., Bianco-Miotto, T., Ryan, N., Thomas, M., . . . Hickey, T. (2014). Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo. Menopause, 21(1), 79-88. DOI Scopus17 WoS13 Europe PMC12
2014	Bianco-Miotto, T., Trotta, A., Need, E., Lee, A., Ochnik, A., Giorgio, L., . . . Buchanan, G. (2014). Molecular and structural basis of androgen receptor responses to dihydrotestosterone, medroxyprogesterone acetate and Delta(4)-tibolone. Molecular and Cellular Endocrinology, 382(2), 899-908. DOI Scopus3 WoS1 Europe PMC1
2014	Rodrigues, D., Butler, L., Estelles, D., & de Bono, J. (2014). Molecular pathology and prostate cancer therapeutics: from biology to bedside. Journal of Pathology, 232(2), 178-184. DOI Scopus35 WoS28 Europe PMC25
2013	Comstock, C., Augello, M., Goodwin, J., de Leeuw, R., Schiewer, M., Ostrander, W., . . . Knudsen, K. (2013). Targeting cell cycle and hormone receptor pathways in cancer. Oncogene, 32(48), 5481-5491. DOI Scopus93 WoS79 Europe PMC72
2013	Philp, L., Butler, M., Hickey, T., Butler, L., Tilley, W., & Day, T. (2013). SGTA: A new player in the molecular co-chaperone game. Hormones and Cancer, 4(6), 343-357. DOI Scopus27 WoS24 Europe PMC24
2013	Trotta, A., Need, E., Selth, L., Chopra, S., Pinnock, C., Leach, D., . . . Buchanan, G. (2013). Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. International Journal of Cancer, 133(12), 2812-2823. DOI Scopus19 WoS18 Europe PMC18
2013	Centenera, M., Raj, G., Knudsen, K., Tilley, W., & Butler, L. (2013). Ex vivo culture of human prostate tissue and drug development. Nature Reviews, Urology, 10(8), 483-487. DOI Scopus112 WoS103 Europe PMC94
2013	Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., . . . Tilley, W. (2013). Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British Journal of Cancer, 109(3), 641-650. DOI Scopus113 WoS110 Europe PMC88
2013	Gillis, J., Selth, L., Centenera, M., Townley, S., Sun, S., Plymate, S., . . . Butler, L. (2013). Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget, 4(5), 691-704. DOI Scopus49 WoS45 Europe PMC39
2013	Abankwa, D., Millard, S., Martel, N., Choong, C., Yang, M., Butler, L., . . . Leong, G. (2013). Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription. BMC Biochemistry, 14(10), 1-9. DOI Scopus14 WoS12 Europe PMC13
2013	Ravindranathan, P., Lee, T., Yang, L., Centenera, M., Butler, L., Tilley, W., . . . Raj, G. (2013). Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nature Communications, 4(5), 1923-1-1923-11. DOI Scopus118 WoS111 Europe PMC83
2013	Centenera, M., Fitzpatrick, A., Tilley, W., & Butler, L. (2013). Hsp90: still a viable target in prostate cancer. Biochimica et Biophysica Acta-Reviews on Cancer, 1835(2), 211-218. DOI Scopus44 WoS39 Europe PMC28
2013	Chiam, K., Ryan, N., Ricciardelli, C., Day, T., Buchanan, G., Ochnik, A., . . . Bianco-Miotto, T. (2013). Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate, 73(2), 182-193. DOI Scopus15 WoS13 Europe PMC12
2012	Betterman, K., Paquet- Fifield, S., Asselin-Labat, M., Visvader, J., Butler, L., Stacker, S., . . . Harvey, N. (2012). Remodeling of the lymphatic vasculature during mouse mammary gland morphogenesis is mediated via epithelial-derived lymphangiogenic stimuli. American Journal of Pathology, 181(6), 2225-2238. DOI Scopus17 WoS15 Europe PMC14
2012	Trotta, A., Need, E., Butler, L., Selth, L., O'Loughlin, M., Coetzee, G., . . . Buchanan, G. (2012). Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. Journal of Molecular Endocrinology, 49(2), 57-68. DOI Scopus19 WoS17 Europe PMC17
2012	Moore, N., Buchanan, G., Harris, J., Selth, L., Bianco-Miotto, T., Hanson, A., . . . Tilley, W. (2012). An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocrine-Related Cancer, 19(4), 599-613. DOI Scopus47 WoS44 Europe PMC32
2012	Selth, L., Tilley, W., & Butler, L. (2012). Circulating microRNAs: macro-utility as markers of prostate cancer?. Endocrine-Related Cancer, 19(4), 99-113. DOI Scopus39 WoS34 Europe PMC29
2012	Dean, J., McClendon, A., Hickey, T., Butler, L., Tilley, W., Witkiewicz, A., & Knudsen, E. (2012). Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle, 11(14), 2756-2761. DOI Scopus189 WoS163 Europe PMC143
2012	Centenera, M., Gillis, J., Hanson, A., Jindal, S., Taylor, R., Risbridger, G., . . . Butler, L. (2012). Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clinical Cancer Research, 18(13), 3562-3570. DOI Scopus94 WoS89 Europe PMC73
2012	Moore, N., Hickey, T., Butler, L., & Tilley, W. (2012). Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Molecular and Cellular Endocrinology, 357(1-2), 60-70. DOI Scopus39 WoS38 Europe PMC21
2012	Thompson, V., Day, T., Bianco-Miotto, T., Selth, L., Han, G., Thomas, M., . . . Tilley, W. (2012). A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. International Journal of Cancer, 131(3), 662-672. DOI Scopus31 WoS28 Europe PMC24
2012	Selth, L., Townley, S., Gillis, J., Ochnik, A., Murti, K., Macfarlane, R., . . . Butler, L. (2012). Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. International Journal of Cancer, 131(3), 652-661. DOI Scopus163 WoS140 Europe PMC121
2012	Schiewer, M., Goodwin, J., Han, S., Brenner, J., Augello, M., Dean, J., . . . Knudsen, K. (2012). Dual roles of PARP-1 promote cancer growth and progression. Cancer Discovery, 2(12), 1134-1149. DOI Scopus336 WoS299 Europe PMC250
2011	Chiam, K., Centenera, M., Butler, L., Tilley, W., & Bianco-Miotto, T. (2011). GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS One, 6(9), e25634-1-e25634-11. DOI Scopus46 WoS36 Europe PMC31
2011	Peters, A., Ingman, W., Tilley, W., & Butler, L. (2011). Differential effects of exogenous androgen and an androgen receptor antagonist in the peri- and postpubertal murine mammary gland. Endocrinology, 152(10), 3728-3737. DOI Scopus53 WoS46 Europe PMC38
2011	Buchanan, G., Need, E., Barrett, J., Bianco-Miotto, T., Thompson, V., Butler, L., . . . Coetzee, G. (2011). Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. Molecular and Cellular Endocrinology, 342(1-2), 20-31. DOI Scopus12 WoS12 Europe PMC12
2010	Bianco-Miotto, T., Chiam, K., Buchanan, G., Jindal, S., Day, T., Thomas, M., . . . Ricciardelli, C. (2010). Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiology Biomarkers & Prevention, 19(10), 2611-2622. DOI Scopus136 WoS112 Europe PMC84
2010	Ochnik, A. M., Jankovic-Karasoulos, T., Cops, E. J., Birrell, S. N., Butler, L. M., Jindall, S., . . . Hickey, T. E. (2010). Medroxyprogesterone acetate impedes 5 alpha-dihydrotesterone induced androgen receptor signaling in normal and malignant human breast epithelial cells. Cancer Research, 70(Suppl 8), 4 pages. DOI
2010	Murti, K., Butler, L. M., Sakko, A., Ricciardelli, C., Mitto, T. B., Octnick, A., . . . Tilley, W. D. (2010). Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Medical Journal of Indonesia, 19(1), 5-13. DOI Scopus2 WoS2
2009	Marrocco, D., Centenera, M., Scher, H., Tilley, W., & Butler, L. (2009). Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert Review of Clinical Pharmacology, 2(6), 619-630. DOI Scopus5 Europe PMC4
2009	Peters, A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M., Harris, J., . . . Tilley, W. (2009). Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Research, 69(15), 6131-6140. DOI Scopus331 WoS295 Europe PMC225
2009	Chiam, K., Tilley, W., Butler, L., & Bianco-Miotto, T. (2009). The dynamic and static modification of the epigenome by hormones: A role in the developmental origin of hormone related cancers. Biochimica et Biophysica Acta-Reviews on Cancer, 1795(2), 104-109. DOI Scopus16 WoS17 Europe PMC11
2008	Centenera, M., Harris, J., Tilley, W., & Butler, L. (2008). The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling. Molecular Endocrinology, 22(11), 2373-2382. DOI Scopus118 WoS103 Europe PMC79
2008	Cops, E., Bianco-Miotto, T., Moore, N., Clarke, C., Birrell, S., Butler, L., & Tilley, W. (2008). Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. Journal of Steroid Biochemistry and Molecular Biology, 110(3-5), 236-243. DOI Scopus60 WoS58 Europe PMC44
2007	Buchanan, G., Ricciardelli, C., Harris, J., Prescott, J., Yu, Z., Jia, L., . . . Tilley, W. (2007). Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine-rich tetratricopeptide repeat containing protein α. Cancer Research, 67(20), 10087-10096. DOI Scopus79 WoS76 Europe PMC64
2007	Birrell, S., Butler, L., Harris, J., Buchanan, G., & Tilley, W. (2007). Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB Journal, 21(10), 2285-2293. DOI Scopus79 WoS67 Europe PMC54
2007	Robzyk, K., Oen, H., Buchanan, G., Butler, L., Tilley, W., Mandal, A., . . . Caplan, A. (2007). Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. Molecular and Cellular Endocrinology, 268(1-2), 67-74. DOI Scopus8 WoS10 Europe PMC8
2007	Marrocco, D., Tilley, W., Bianco-Miotto, T., Evdokiou, A., Scher, H., Rifkind, R., . . . Butler, L. (2007). Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Molecular Cancer Therapeutics, 6(1), 51-60. DOI Scopus94 WoS83 Europe PMC71
2006	Butler, L., Liapis, V., Bouralexis, S., Welldon, K., Hay, S., Thai, L., . . . Evdokiou, A. (2006). The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. International Journal of Cancer, 119(4), 944-954. DOI Scopus72 WoS64 Europe PMC48
2006	Butler, L., Centenera, M., Neufing, P., Buchanan, G., Choong, C., Ricciardelli, C., . . . Tilley, W. (2006). Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Molecular Endocrinology, 20(5), 1009-1024. DOI Scopus15 WoS14 Europe PMC11
2005	Buchanan, G., Birrell, S., Peters, A., Bianco-Miotto, T., Ramsay, K., Cops, E., . . . Tilley, W. (2005). Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Research, 65(18), 8487-8496. DOI Scopus62 WoS58 Europe PMC48
2005	Shen, H., Buchanan, G., Butler, L., Prescott, J., Henderson, M., Tilley, W., & Coetzee, G. (2005). GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.. Journal of Biological Chemistry, 386(1), 69-74. DOI Scopus25 WoS25 Europe PMC17
2005	Wold, R. S., Lopez, S. T., Yau, C. L., Butler, L. M., Pareo-Tubbeh, S. L., Waters, D. L., . . . Baumgartner, R. N. (2005). Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. Journal of the American Dietetic Association, 105(1), 54-63. DOI Scopus88
2004	Wayne, S. J., Lopez, S. T., Butler, L. M., Baumgartner, K. B., Baumgartner, R. N., & Ballard-Barbash, R. (2004). Changes in dietary intake after diagnosis of breast cancer. Journal of the American Dietetic Association, 104(10), 1561-1568. DOI Scopus79 Europe PMC55
2004	Scher, H., Buchanan, G., Gerald, W., Butler, L., & Tilley, W. (2004). Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer, 11(3), 459-476. DOI Scopus209 WoS201 Europe PMC148
2003	Kutko, M., Glick, R., Butler, L., Coffey, D., Rifkind, R., Marks, P., . . . LaQuaglia, M. (2003). Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clinical Cancer Research, 9(15), 5749-5755. Scopus59 WoS56 Europe PMC39
2002	Butler, L., Zhou, X., Marks, P., Rifkind, R., & Richon, V. (2002). The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proceedings of the National Academy of Sciences of the United States of America, 99(18), 11700-11705. DOI Scopus476 WoS452 Europe PMC326
2001	Butler, L., Webb, Y., Agus, D., Higgins, B., Tolentino, T., Kutko, M., . . . Marks, P. (2001). Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clinical Cancer Research, 7(4), 962-970. Scopus128 WoS119 Europe PMC62
2001	Babidge, W., Butler, L., Burton, M., & Cowled, P. (2001). Methylation of CpG sites in exon 2 of the Bcl-2 gene occurs in colorectal carcinoma. Anticancer Research, 21(4A), 2809-2814. Scopus16 WoS13 Europe PMC10
2001	Coffey, D., Kutko, M., Glick, R., Butler, L., Heller, G., Rifkind, R., . . . LaQuaglia, M. (2001). The histone deacetylase inhibitor CBHA inhibits growth of human neuroblastoma xenografts in vivo alone and synergistically with all-trans retinoic acid. Cancer Research, 61(9), 3591-3594. Scopus160 WoS147 Europe PMC86
2000	Butler, L., Dobrovic, A., Bianco-Miotto, T., & Cowled, P. (2000). Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma. British Journal of Cancer, 82(1), 131-135. DOI Scopus21 WoS18 Europe PMC21
2000	Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon-Cardo, C., . . . Richon, V. M. (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Research, 60(18), 5165-5170. Scopus601 WoS564 Europe PMC378
2000	Coffey, D. C., Kutko, M. C., Glick, R. D., Swendeman, S. L., Butler, L., Rifkind, R., . . . LaQuaglia, M. P. (2000). Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Medical and Pediatric Oncology, 35(6), 577-581. DOI Scopus62 WoS59 Europe PMC35
1999	Butler, L., Hewett, P., Fitridge, R., & Cowled, P. (1999). Deregulation of apoptosis in colorectal carcinoma: theoretical and therapeutic implications. Australian and New Zealand Journal of Surgery, 69(2), 88-94. DOI Scopus43 WoS41 Europe PMC27
1999	Leonardos, L., Butler, L., Hewett, P., Zalewski, P., & Cowled, P. (1999). The activity of caspase-3-like proteases is elevated during the development of colorectal carcinoma.. Cancer Letters, 143(1), 29-35. DOI Scopus19 WoS15 Europe PMC12
1998	Butler, L., Hewett, P., Butler, W., & Cowled, P. (1998). Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. British Journal of Cancer, 77(9), 1454-1459. DOI Scopus42 WoS39 Europe PMC29
1997	Harkin, L., Butler, L., & Burcham, P. (1997). Role of G-T transversions in the mutagenicity of alkylperoxyl radicals: induction of alkali-labile sites in bacteriophage M13 mp19.. Chemical Research in Toxicology, 10(5), 575-581. DOI Scopus17 WoS17 Europe PMC4

Book Chapters

Year	Citation
2014	Moore, N., Centenera, M., Butler, L., Hickey, T., & Tilley, W. (2014). Androgens and the androgen receptor (AR). In E. Gelmann, C. Sawyers, & F. Rauscher (Eds.), Molecular oncology: Causes of cancer and targets for treatment (1 ed., pp. 378-391). Cambridge, United Kingdom: Cambridge University Press. DOI
2013	Selth, L., Townley, S., Gillis, J., Tilley, W., & Butler, L. (2013). Identification of prostate cancer-associated microRNAs in circulation using a mouse model of disease. In T. Ochiya (Ed.), Circulating MicroRNAs. Methods and Protocols (Vol. 1024, pp. 235-246). UK: Springer. DOI Scopus3 Europe PMC3
2013	Selth, L. A., Townley, S. L., Gillis, J. L., Tilley, W. D., & Butler, L. M. (2013). Identification of Prostate Cancer-Associated MicroRNAs in Circulation Using a Mouse Model of Disease. In Methods in Molecular Biology (pp. 235-246). Humana Press. DOI
2009	Buchanan, G., Need, E., Bianco-Miotto, T., Greenberg, N., Scher, H., Centenera, M., . . . Tilley, W. (2009). Insights from AR gene mutations. In D. Tindall, & J. Mohler (Eds.), Androgen action in prostate cancer (pp. 207-240). Dordrecht, Netherlands: Springer. DOI Scopus4

Conference Papers

Year	Citation
2022	Mak, B., Lin, H. -M., Mahon, K. L., Joshua, A. M., Stockler, M. R., Gurney, H., . . . Horvath, L. (2022). Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40 (pp. 3 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. DOI
2017	Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Butler, L. (2017). Lipid elongation: an unexplored therapeutic target in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH. DOI
2017	Shafi, A. A., Schiewer, M. J., de Leeuw, R., McCue, P. A., Gomella, L. G., Lallas, C. D., . . . Knudsen, K. E. (2017). PDeX (Patient Derived eXplant) models to determine the basis for response to targeted agents in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH. DOI
2017	Tran, L. N. K., Kichenadasse, G., Ormsby, R. J., Morel, K. L., Butler, L. M., Centenera, M. M., & Sykes, P. J. (2017). COMBINATION OF METFORMIN AND SODIUM VALPROATE FOR PROSTATE CANCER: A RAPID APPROACH FROM BENCH TO CLINICAL TRIAL.. In JOURNAL OF UROLOGY Vol. 197 (pp. E1108-E1109). Boston, MA: ELSEVIER SCIENCE INC. DOI
2016	Tran, L. N. K., Kichenadasse, G., Morel, K. L., Ormsby, R. J., Butler, L. M., Centenera, M. M., & Sykes, P. J. (2016). Combination of metformin and valproic acid in personalized prostate cancer treatment: the role of p53 and androgen receptor signaling. In CANCER RESEARCH Vol. 76 (pp. 4 pages). New Orleans, LA: AMER ASSOC CANCER RESEARCH.
2016	Oesterreich, S., Katz, T., Logan, G., Levine, K., Nagle, A., Huo, Z., . . . Butler, L. (2016). Potential role of prolactin signaling in development and growth of the lobular subtype of breast cancer. In CANCER RESEARCH Vol. 76 (pp. 1 page). San Antonio, TX: AMER ASSOC CANCER RESEARCH. DOI
2016	Jankowitz, R., McAuliffe, P., Sikora, M., Butler, L., Ahrendt, G., Johnson, R., . . . Oesterreich, S. (2016). A neoadjuvant window trial of endocrine response in women with invasive lobular carcinoma. In CANCER RESEARCH Vol. 76 (pp. 2 pages). San Antonio, TX: AMER ASSOC CANCER RESEARCH. DOI
2015	Johnson, I. R. D., Parkinson-Lawrence, E. J., Butler, L. M., O'Leary, J. J., & Brooks, D. A. (2015). Altered Endosome Biogenesis in Prostate Cancer Has Prognostic Potential. In JOURNAL OF PATHOLOGY Vol. 237 (pp. S17). Univ Coll D, Dublin, IRELAND: WILEY-BLACKWELL.
2012	Ochnik, A. M., Moore, N. L., Birrell, S. N., Butler, L. M., Jindal, S., Selth, L., . . . Hickey, T. E. (2012). The combined actions of DHT and MPA lead to altered AR signaling in normal and malignant post-menopausal breast epithelial cells. In Cancer Research Vol. 72 (pp. 2). Chicago, IL: American Association for Cancer Research. DOI
2009	Lee, M., Labrinidis, A., Liapis, V., Hay, S., Zinonos, I., Butler, L., . . . Evdokiou, A. (2009). The histone deacetylase inhibitor, LBH589 blocks osteoclastogenesis, enhances osteoblast activity and reduces tumor burden in bone. In CANCER RESEARCH Vol. 69 (pp. 1 page). AMER ASSOC CANCER RESEARCH.
2009	Butler, L., Centenera, M., Marrocco, D., Carter, S., Bianco-Miotto, T., & Tilley, W. (2009). A novel combinatorial approach using androgen receptor-targeted agents for treatment of prostate cancer. In Cancer Research Vol. 69 (pp. 2 pages). American Association for Cancer Research.
2006	Murphy, N., Bianco-Miotto, T., Ricciardelli, C., Ruiz, A., Segara, D., McNeil, C., . . . Tilley, W. (2006). Expression of the androgen receptor and its association with disease outcome in breast cancer. In Breast Cancer Research and Treatment Vol. 100 (pp. S262-S263). San Antonio, Texas: Springer.
2005	Evdokiou, A., Minh, L. T., Labrinidis, A., Hay, S., Liapis, V., Bouralexis, S., . . . Findlay, D. M. (2005). Apo2L/TRAIL is a potent anticancer agent that prevents breast cancer-induced bone destruction in a mouse model. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 20 (pp. P35). Bethesda, MD: AMER SOC BONE & MINERAL RES.

Conference Items

Year	Citation
2023	Horvath, L., Lin, H. -M., Huynh, K., Meikle, T., Joshua, A. M., Azad, A., . . . Meikle, P. (2023). Circulating ether lipids in prostate cancer. Poster session presented at the meeting of Abstracts of the American Society of Clinical Oncology Annual Meeting I (ASCO 2023), as published in Journal of Clinical Oncology. Chicago, IL: Lippincott Williams & Wilkins. DOI
2023	Cilento, M. A., Mah, C. Y., Martelotto, L., Sweeney, C. J., & Butler, L. M. (2023). Multiomic analysis workflow for biomarker discovery in human prostate cancer. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2022	Strach, M. C., Yeung, N., Lin, H. -M., Ansari, N., Koh, C., Shin, J. -S., . . . Mahon, K. (2022). Patient-derived explant model of appendiceal cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2021	Lin, H. -M., Mak, B., Huynh, K., Kwan, E. M., Fettke, H., Tran, B., . . . Horvath, L. G. (2021). Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer. Poster session presented at the meeting of Abstracts of the European Society for Medical Oncology Congress (ESMO 2021), as published in Annals of Oncology. online: Elsevier. DOI
2020	Lin, H. -M., Huynh, K., Kohli, M., Tan, W., Azad, A., Yeung, N., . . . Horvath, L. (2020). Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism. Poster session presented at the meeting of Abstracts of the Mini Annual Scientific Meeting ANZUP 2020, as published in Asia-Pacific Journal of Clinical Oncology. Adelaide, SA: Wiley.
2020	Gieniec, K., Kobayashi, H., Lannagan, T., Wang, T., Asai, N., Mizutani, Y., . . . Worthley, D. (2020). Melanoma cell adhesion molecule defines a proliferative subset of leptin receptor-lineage cells that substantially contribute to the colorectal cancer stroma. Poster session presented at the meeting of JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY.
2020	Kobayashi, H., Gieniec, K., Wright, J., Wang, T., Asai, N., Mizutani, Y., . . . Woods, S. (2020). Stromal imbalance of bone morphogenetic protein signaling drives colorectal carcinogenesis. Poster session presented at the meeting of JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY.
2020	Shrestha, R. K., Townley, S., Hanson, A., Pickering, M., Nassar, Z. D., Mah, C. Y., . . . Selth, L. A. (2020). ACSM1 and ACSM3 regulate fatty acid oxidation in prostate cancer to promote growth and protect against oxidative stress.. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH. WoS1
2020	Horvath, L. G., Lin, H. -M., Mak, B., Mahon, K., Yeung, N., Docanto, M., . . . Butler, L. (2020). Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH. DOI
2020	Butler, L. M., Mah, C. Y., Dehairs, J., Vincent, A., Mutuku, S., Spotbeen, X., . . . Swinnen, J. (2020). Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH. DOI
2020	Mah, C. Y., Nassar, Z. D., Burvenich, I. J., Irani, S., Centenera, M. M., Moldovan, M., . . . Butler, L. M. (2020). DECR1: The rate limiting enzyme of polyunsaturated fatty acid metabolism and a novel therapeutic target in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH. DOI
2019	Shafi, A. A., Schiewer, M. J., de Leeuw, R., Dylgjeri, E., Mccue, P. A., Shah, N., . . . Knudsen, K. E. (2019). Patient derived models reveal impact of the tumor microenvironment on therapeutic response. Poster session presented at the meeting of CANCER RESEARCH. Atlanta, GA: AMER ASSOC CANCER RESEARCH. DOI
2019	Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., Sebastian, L., Stricker, P., . . . Horvath, L. G. (2019). Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (Ribociclib) in High-Risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (Leep Study). Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2019	Butler, L., Irani, S., Centenera, M., Ryan, N., Pegg, N., & Brooks, A. N. (2019). Preclinical investigation of a small molecule inhibitor of p300/CBP reveals efficacy in patient-derived prostate tumor explants.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS2
2018	Mutuku, S. M., Centenera, M. M., Trim, P. J., Snel, M. F., & Butler, L. M. (2018). Evaluation of small molecule drug uptake in <i>ex vivo</i> cultured clinical prostate tumours by mass spectrometry. Poster session presented at the meeting of BJU INTERNATIONAL. Brisbane, AUSTRALIA: WILEY.
2018	Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Adelaide: Wiley.
2018	Nassar, Z. D., Centenera, M. M., Machiels, J., Zinonos, I., Hanson, A., Bloch, K., . . . Swinnen, J. V. (2018). Lipid elongation in prostate cancer is androgen regulated and a potential therapeutic target. Poster session presented at the meeting of BJU International. Brisbane, Australia: Wiley.
2018	Butler, L. M. (2018). New Insights into Prostate Tumour Heterogeneity from Studying the "Lipidome". Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2018	Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Sydney: Wiley.
2018	Zhang, A. Y., Chiam, K., Haupt, Y., Fox, S. B., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy. Poster session presented at the meeting of Journal of Clinical Oncology. San Francisco, CA: American Society of Clinical Oncology. DOI
2017	Mutuku, S. M., Centenera, M., Trim, P., Gustafsson, O. J., Snel, M., & Butler, L. (2017). A Mass Spectrometry Approach to Characterise Lipid Composition in Prostate Tumuors. Poster session presented at the meeting of 11th Florey Postgraduate Research Conference. Adelaide.
2017	Aref, A. T., Vincent, A., O'Callaghan, M., Hoy, A., Butler, L., & Wittert, G. (2017). The inverse relationship between prostate specific antigen (PSA) and obesity in healthy men; support for a hormonal, rather than haemodilution mechanism. Poster session presented at the meeting of Abstracts of the 2017 ANZUP Annual Scientific Meeting, as published in Asia-Pacific Journal Of Clinical Oncology. Melbourne, VIC: Wiley. DOI
2017	Mutuku, S. M., Prabhala Bala., Centenera, M., Trim, P., Snel, M., & Butler, L. (2017). Quantification of Enzalutamide in Cultured Prostate Tissue Using LC-MS/MS. Poster session presented at the meeting of 26th Australian and New Zealand Society for Mass Spectrometry. Flinders University.
2017	Butler, L. (2017). IDENTIFICATION OF DRUG RESPONSE BIOMARKERS IN PATIENT-DERIVED PROSTATE EXPLANTS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2016	Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Swinnen, J. V. (2016). Androgenic regulation of lipid elongation in prostate cancer. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2015	Johnson, I. R. D., Parkinson-Lawrence, E. J., Brooks, D. A., Butler, L., & O'Leary, J. J. (2015). Altered Endosome Biogenesis in Prostate Cancer Identifies Potential Diagnostic Biomarkers. Poster session presented at the meeting of JOURNAL OF PATHOLOGY. Univ Coll D, Dublin, IRELAND: WILEY-BLACKWELL.
2015	Armstrong, H., Butler, L., Selth, L., Tarulli, G., & Centenera, M. (2015). The Hsp90 inhibitor, NVP-AUY922, produces anti-tumour activity through inhibition of fibronectin polymerization resulting in cytoskeletal reorganization. Poster session presented at the meeting of BJU INTERNATIONAL. Cairns, AUSTRALIA: WILEY-BLACKWELL.
2014	Roberts, M., Selth, L., Chow, C., Doi, S., Vincent, A., Butler, L., . . . Gardiner, R. (2014). Seminal fluid microRNAs: new, non-invasive biomarkers for prostate cancer. Poster session presented at the meeting of BJU International. Brisbane: Wiley.
2014	Zhang, A. Y., Butler, L. M., Stricker, P. D., Kench, J. G., Tilley, W. D., Sebastian, L., . . . Horvath, L. (2014). Pharmacodynamic effects of the heat shock protein 90 (HSP90) inhibitor, AUY922, in high-risk, localised prostate cancer. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley. DOI WoS1
2014	Philp, L. K., Day, T. K., Butler, M. S., Jindal, S., Butler, L. M., & Tilley, W. D. (2014). Full, but Not Partial, Sgta Ablation Confers Subfertility and Limits Offspring Viability and Growth in Mice. Poster session presented at the meeting of ENDOCRINE REVIEWS. ENDOCRINE SOC.
2014	Zhuang., Rodriguez Lopez., Chiam, K., Harryanto, H., Ryan, N., Jindal, S., . . . Bianco-Miotto. (2014). A high fat diet early in life and prostate cancer risk. Poster session presented at the meeting of The Australian Health and Medical Research Congress. Melbourne, Australia.
2013	Philp, L., Day, T., Jindal, S., Pickering, M., Butler, L., & Tilley, W. (2013). Protein expression alterations in a unique gleason prostate cancer progression cohort. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2013	Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., . . . Tilley, W. (2013). CIRCULATING microRNAs PREDICT BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
2012	Butler, L. M. (2012). DEVELOPMENTAL THERAPEUTICS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
2010	Centenera, M. M., Treloar, J. L., Hanson, A., Sutherland, P., Tilley, W. D., & Butler, L. M. (2010). Evaluation of the synthetic heat shock protein 90 inhibitors NVP-AUY922 and NVP-HSP990 in human prostate cancer tissue. Poster session presented at the meeting of European Journal of Cancer Supplements. Berlin, Germany: Elsevier. DOI
2008	Hickey, T., Ocknik, A., Bianco-Miotto, T., Birrell, S., Butler, L., & Tilley, W. (2008). Functional androgen signaling in an explant model of normal human breast tissue. Poster session presented at the meeting of Biology of Reproduction. Kailua-Kona, Hawaii: Oxford University Press. DOI
2006	Buchanan, G., Ricciardelli, C., Prescott, J., Harris, J. M., Yu, Z. C. -L., Jia, L., . . . Tilley, W. D. (2006). αSGT: A critical determinant of androgen receptor function in prostate cancer. Poster session presented at the meeting of Cancer Research. Washington, DC: American Association for Cancer Research.

Patents

Year	Citation
2020	Brooks, D., Parkinson-Lawrence, E., Johnson, I., & Butler, L. (2020). 15/794,270, Methods for detecting prostate cancer by determining the ratio of early to late endosomal markers. United States.
2020	Brooks, D., O'Leary, J., Logan, J., Sorvina, A., Martino, C., Johnson, I., . . . Butler, L. (2020). PCT/AU2020/050925, Methods for Confirming Detection and Evaluating the Progression of a Prostate Cancer - II. Australia.
2014	Brooks, D., Parkinson-Lawrence, E., Johnson, I., Butler, L., & Weigert, R. (2014). PCT/AU2014/000612, Methods for detecting prostate cancer. Australia.
2003	Richon, V., Marks, P., Rifkind, R., & Butler, L. (2003). WO/2003/070188, Method of treating TRX mediated inflammatory diseases. United States Patent US2003235588.

Preprint

Year	Citation
2023	Cook, D., Jensen, K., Wise, K., Roach, M., Dezem, F. S., Ryan, N., . . . Martelotto, L. (2023). A Comparative Analysis of Imaging-Based Spatial Transcriptomics Platforms. DOI
2023	Wang, T., Harvey, K., Morlanes, J. E., Kiedik, B., Al-Eryani, G., Greenwald, A., . . . Martelotto, L. (2023). snPATHO-seq: unlocking the pathology archives. DOI
2023	Jiménez-Gracia, L., Marchese, D., Nieto, J., Caratù, G., Melón-Ardanaz, E., Gudiño, V., . . . Martelotto, L. (2023). FixNCut: Single-cell genomics through reversible tissue fixation and dissociation. DOI

FELLOWSHIPS

Cancer Council of SA Beat Cancer Principal Research Fellowship. BUTLER LM. From bedside to bench to bedside: improving prognosis and treatment of prostate cancer. 2018-2022. $600,000.
Australian Research Council Future Fellowship. BUTLER LM. Molecular hallmarks of androgen receptor targeting in prostate cancer. 2014-2018. $846,240.
Cancer Council of SA Senior Research Fellowship. BUTLER LM. Androgen Signalling in the normal human breast: role and implications for breast cancer risk. 2008-2012. $276,000.
Royal Adelaide Hospital/IMVS Florey Research Fellowship. BUTLER LM. The role of androgen receptor signalling in the normal human breast. 2006-2008. $237,180.
Prostate Cancer Foundation of Australia Postdoctoral Fellowship. BUTLER LM. Dominant negative androgen receptors: a novel strategy for treatment of advanced prostate cancer. 2003-2005. $300,000.

GRANT FUNDING

Australian Research Council Discovery Project. BUTLER LM, Selth LA, Hoy AJ, Lynn DJ, Swinnen JV. Androgen receptor: a master regulator of lipid metabolism. 2023-2026. $614,000.
Cancer Council NSW. BUTLER LM, Centenera MM. A patient-derived platform for drug development in prostate cancer. 2022-2025. $433,228.
US Department of Defense. Labbe D, Corey E, Mucci L, Horvath L, Butler LM. Precision nutrition increases efficacy of DNA-damaging therapies in prostate cancer. 2022-2027. $USD 2,000,000.
Cancer Australia. Selth LA, Wang S, BUTLER LM, Taylor RA, Holst J. Targeting CDK9 in lethal prostate cancer. 2022-2025. $459,000.
Cancer Council of SA Women in Leadership Award. BUTLER LM. 2021. $59,976.
The Hospital Research Foundation Prostate Cancer Project Grant. Centenera MM, BUTLER LM, Horvath LG. A patient-derived discovery platform for companion biomarker development in prostate cancer. 2021-2022. $149,662.
The Hospital Research Foundation Prostate Cancer Project Grant. Nassar ZD, Xie J, BUTLER LM, Selth LA. Targeting Fatty Acid Oxidation for Treatment of High Risk Localised Prostate Cancer. 2021-2022. $149,956.
Medical Research Future Fund Biomedical Translation Bridge (MTP Connect) / Envision Sciences Pty. Ltd./University of South Australia. Brooks DA, O’Leary JJ, Pursey P, Morretti K, Klebe S, Samaratunga H, Delahunt B, Karageorgos L, Esterman A, Dinan A, Brooks RD, Logan J, Sorvina A, Martino C, BUTLER L, Ung B Diagnosis and prognosis of prostate cancer using blood and tissue tests. 2020-21. $2,400,000.
Tour de Cure Project Grant. Holst J, BUTLER LM. A new therapy targeting “gluttonous” prostate cancer cells. 2020-2021. $200,000.
US Department of Defense Prostate Cancer Research Program Idea Development Award. Loda M, BUTLER LM, Swinnen JV. Lipid elongation via ELOVL5: a novel target for advanced prostate cancer. 2019-2022. $USD 736,817.
UniSA Division of Health Sciences and UniSA Innovation Services. Brooks DA, Logan J, Martino C, Sorvina A, Johnson I, BUTLER L, Selemidis S, O’Leary J, Pursey P. UniSA Support Grant for Cancer Research Translation Programme. 2019-2022. $1,632,000.
Cancer Australia Project Grant. BUTLER LM, Lynn DJ, Hayes VM, Horvath LG, Mills IG and Centenera MM. Novel co-extinction strategies for treatment of prostate cancer. 2017-2021. $596,409.
Cancer Australia Project Grant. BUTLER LM, Horvath LJ, Tilley WD, Stocker M, Stricker PD and Kench JD. A randomised controlled Phase II trial of the pharmacodynamic effects of the Cdk4/6 inhibitor, LEE011, in high-risk, localised prostate cancer. 2016-2020. $590,408.
Movember Foundation / Prostate Cancer Foundation of Australia Revolutionary Team Award. BUTLER LM, Swinnen JV, Tilley WD, Scott AM, Hoy AJ and Wittert GA. Exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancer. Phase 1: 2015-2018. $3,250,000. Phase 2: 2019-2021. $2,000,000.
Prostate Cancer Foundation of Australia Novel Concept Grant. BUTLER LM and Voelcker N. Next-generation prostate cancer therapies based on precision nanomedicines. 2017-2018. $99,919.
Cancer Australia Project Grant. BUTLER LM, Daly R, Tilley WD, Horvath LG and Centenera MM. Molecular hallmarks of heat shock protein 90 inhibition in prostate cancer. 2015-2018. $553,483.
NHMRC Development Grant. Brooks DA, BUTLER LM and O’Leary JJ. Development of effective biomarkers for the diagnosis and prognosis of Prostate Cancer. 2015-2017. $1,029,873.
Cancer Australia Project Grant. Tilley WD, BUTLER LM, Plymate S and Selth LA. Mechanism and targeting of castration resistant prostate cancer. 2013-2015. $586,398.
Ray and Shirl Norman Cancer Research Trust Research Grant. Tilley WD, BUTLER LM, Selth LA and Parnis F. Targeting androgen receptor variant signalling in lethal prostate cancer. 2013-2014. $327,184.
Royal Adelaide Hospital Clinical Project Grant. Centenera MM and BUTLER LM. Evaluation of biomarkers of response to Hsp90 inhibition in human prostate cancer. 2013. $48,000.
Royal Adelaide Hospital Clinical Project Grant. BUTLER LM, Brook N, Sutherland P and Saunders P. Development of an Australian prostate cancer reference cohort to support research identifying better biomarkers that predict disease progression. 2013. $18,000.
Prostate Cancer Foundation of Australia New Directions Development Award. BUTLER LM, Centenera MM, Claessens F and Swinnen JV. Exploiting metabolic alterations to more accurately monitor prostate cancer therapy. 2012-2013. $299,817.
Cancer Australia Project Grant. Tilley WD, BUTLER LM, Hoffman P, Goodall G and Scher HI. A novel approach to predict metastatic potential at prostate cancer diagnosis. 2011-2013. $591,732.
Prostate Cancer Foundation of Australia Project Grant. Buchanan G, Kee T and BUTLER LM. Targeting chemokine signalling in prostate cancer. 2011-2012. $250,000.
RAH/IMVS Research Committee Clinical Project Grant. Centenera MM, BUTLER LM and Tilley WD. Identification of biomarkers of response to Hsp90 inhibition in human prostate cancer. 2011. $20,000.
Cancer Australia/Prostate Cancer Foundation of Australia Project Grant. BUTLER LM, Tilley WD and Scher HI. A combinatorial approach targeting androgen signalling for treatment of prostate cancer. 2010-2012. $589,673.
NHMRC Project Grant. Tilley WD, BUTLER LM, Scher H and Bianco-Miotto T. The essential role of androgen receptor signalling in prostate tumorigenesis. 2010-2012. $813,913.
RAH/IMVS Research Committee Clinical Project Grant. BUTLER LM. A novel explant model for the investigation of hormone signalling and novel treatments in human prostate tissue. 2010. $20,000.
NHMRC Project Grant. Evdokiou A, Findlay DM and BUTLER LM. Histone Deacetylase Inhibitors (HDIs) with antineoplastic and antiosteolytic properties. 2008-2010. $513,750.
US Army Medical Research and Material Command Congressionally Directed Medical Research Programs. Tilley WD, BUTLER LM and Marshall VR. Mechanism of Prostate Cancer Tumorigenesis. 2007-2010. $USD 482,622.
NHMRC Project Grant. Tilley WD, BUTLER LM and Marshall VR. Androgen receptor signalling in development and progression of prostate cancer. 2007-2009. $723,750.
National Breast Cancer Foundation of Australia. Androgen receptor status as a determinant of breast cancer risk. Tilley WD, BUTLER LM, Roder DM and Gelareh F. 2007-2008. $168,000.
US Army Medical Research and Material Command Congressionally Directed Medical Research Programs. Kennaway DJ, Tilley WD and BUTLER LM. Disruption of the circadian rhythms of gene expression and the development of breast cancer. 2006-2008. $USD 381,818.
National Breast Cancer Foundation of Australia. Evdokiou A, BUTLER LM and Findlay DM. TRAIL in breast cancer therapy. 2006-2008. $254,004.
Cancer Council of South Australia. Tilley WD, BUTLER LM, Roder D and Farshid G. Androgen receptor status as a determinant of breast cancer risk. 2006. $76,000.
The Susan G Komen Breast Cancer Foundation. BUTLER LM, Tilley WD and Birrell SN. Role of androgen signalling in the breast: disruption by synthetic progestins. 2005-2008. $USD 333,332.
Cancer Council of South Australia. Evdokiou A, BUTLER LM and Findlay DM. Inhibition of breast cancer growth in, and metastasis to, bone using TRAIL therapy. 2005. $64,125.
NHMRC Project Grant. Tilley WD, BUTLER LM and Marshall VR. Androgen receptor signalling and progression of prostate cancer. 2004-2006. $455,250,
US Army Medical Research and Materiel Command, Breast Cancer Research Program. Kennaway DJ, BUTLER LM and Tilley WD. Clock genes: critical modulators of breast cancer risk? 2004-2005. $USD 99,485.
US Army Medical Research and Materiel Command. Tilley WD, BUTLER LM and Birrell SN. The role of androgen receptor signalling in breast cancer. 2003-2006. $USD 350,121.
NHMRC Project Grant. Tilley WD, BUTLER LM and Birrell SN. Inhibition of estrogen signalling by the androgen receptor: a potential mechanism of suppression of breast cancer cell growth by androgens. 2003-2005. $375,000.

PREVIOUS COMMERCIAL FUNDING

Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, O’Leary JJ, Brooks RD, Logan J, Sorvina A, Martino C, BUTLER L, Johnson I, Hickey S, Selemidis S, Parkinson-Lawrence EJ, Orgeig S, Lazniewska J, Thomas C, Dale B, Ung B, Bader C, Morrow I, Chappell N, Moore C, Reynolds P, Esterman A, Karageorgos L. Development Program: Biomarkers and therapeutics for prostate and other cancers. 2020. $2,000,000.
Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, O’Leary JJ, Brooks RD, Logan J, Sorvina A, Martino C, BUTLER L, Johnson I, Hickey S, Selemidis S, Parkinson-Lawrence EJ, Orgeig S, Lazniewska J, Thomas C, Dale B, Ung B, Bader C, Reynolds P, Esterman A, Olver I. Companion diagnostics and therapeutics for cancer. 2019. $2,350,000.
AusHealth Project Grant. BUTLER LM, Ranieri E. Lipid screening for prostate cancer prognosis. 2018-2020. $200,000.
Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, Plush S, Massi M, Brooks RD, O’Leary JJ, BUTLER L, Sorvina A, Bader C. Visualising the pathogenesis in cancer and developing novel therapeutics. 2017-2018. $1,019,225.
Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, O’Leary JJ, BUTLER L, Johnson I, Selemidis S, Parkinson-Lawrence EJ, Sorvina A, Olver I, Esterman A. Prostate cancer diagnosis and prognosis. 2017-19. $2,930,165.

EQUIPMENT FUNDING

Australian Cancer Research Foundation. Hughes TP, Zannettino ACW, White DL, Proud CG, Wesselingh SL, Lynn DJ, BUTLER LM, Gronthos S, Tilley WD and Bulone V. ACRF Centre for Integrated Cancer Systems Biology. 2018-2022. $2,500,000.

In addition to her extensive supervision of post-graduate students, Prof Butler has several roles in undergraduate teaching at The University of Adelaide.

LECTURING

Biochemistry III – 3 lectures/year (2016-present)
Masters of Biotechnology (Biomedical) – 1 lecture/year (2014-2017)
Comparative Reproductive Biology of Mammals III - 1 lecture/year (2011-2017)
Structural Cell Biology III – 6 lectures/year (2011-2016)

LABORATORY SUPERVISION

Laboratory-based research projects as part of Level 3 Physiology and Medical Science, and Level 3 Biochemistry (2003-present)
Summer vacation projects and scholarship program (2003-present)

STATE-WIDE RESEARCH TRAINING

Teaching of annual workshop on Human Ethics for Laboratory Research- provided to all higher degree research students from the University of Adelaide, UniSA and Flinders University of SA (2009-2012)

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2024	Principal Supervisor	Discovering lipid biomarkers of response to ribociclib in clinical prostate cancer tissues	Doctor of Philosophy	Doctorate	Full Time	Miss Suzanne Rajesh
2023	Co-Supervisor	Novel Target Discovery for TP53 Mutated clonal Haematopoiesis	Doctor of Philosophy	Doctorate	Full Time	Mr Hossein Anani
2023	Principal Supervisor	The impact of high fat diet on plasma ceramides and prostate tumour metastasis	Doctor of Philosophy	Doctorate	Full Time	Miss An Dieu Trang Nguyen
2023	Principal Supervisor	Identifying novel metabolic drivers of lethal prostate cancer	Doctor of Philosophy	Doctorate	Full Time	Dr Michael Adam Cilento
2023	Co-Supervisor	Examining the Influence of Fatty Acid Oxidation on Prostate Cancer Progression: An Epigenetic Exploration.	Doctor of Philosophy	Doctorate	Full Time	Mr Ez Aldeen Ismael Esawi
2023	Co-Supervisor	Synthetic lethality-based identification of metabolic targets for prostate cancer treatment	Doctor of Philosophy	Doctorate	Full Time	Mr Mohammad Asaad Ibrahim Ismail
2023	Co-Supervisor	How pluripotent transcription factors reshape the prostate cancer epigenetic landscape to reprogram the cell fate toward neuroendocrine-like with their cofactors	Doctor of Philosophy	Doctorate	Full Time	Mr Tianjun Zhang
2021	Co-Supervisor	Overcoming resistance to cyclin-dependent kinase inhibition in prostate cancer	Doctor of Philosophy	Doctorate	Full Time	Mr Joshua Thomas Hodgson
2021	Principal Supervisor	Spatial Lipidomics in Clinical Prostate Cancer	Doctor of Philosophy	Doctorate	Full Time	Mr Jacob Truong

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2020 - 2024	Co-Supervisor	Investigating How Fatty Acid Elongation Promotes Prostate Carcinogenesis	Doctor of Philosophy	Doctorate	Full Time	Miss Deanna Catherine Miller
2019 - 2023	Principal Supervisor	Lipid elongation and its role in prostate cancer	Doctor of Philosophy	Doctorate	Full Time	Miss Julia Steele Scott
2019 - 2023	Co-Supervisor	Investigating USP2 as a mediator of therapy resistance in lethal prostate cancer	Doctor of Philosophy	Doctorate	Full Time	Ms Meiwen Danielle Fang
2018 - 2021	Principal Supervisor	Investigating the Contribution of Specific Cancer-Associated Fibroblast Subsets to Colorectal Tumourigenesis	Doctor of Philosophy	Doctorate	Full Time	Miss Krystyna Anna Gieniec
2018 - 2024	Principal Supervisor	Novel co-targets to improve androgen receptor inhibition in prostate cancer	Doctor of Philosophy under a Jointly-awarded Degree Agreement with	Doctorate	Full Time	Miss Josephine Ataa Hinneh
2018 - 2021	Principal Supervisor	Targeting fatty acid metabolism in prostate cancer	Doctor of Philosophy	Doctorate	Full Time	Miss Chui Yan Mah
2017 - 2021	Co-Supervisor	Elucidating the molecular mechanisms underlying androgen-regulated lipid metabolism in prostate cancer	Doctor of Philosophy	Doctorate	Full Time	Mr Raj Kumar Shrestha
2016 - 2019	Principal Supervisor	Defining the Role of Lipids and Metabolic Factors as Risk Factors for Prostate Cancer Incidence and Aggressiveness	Doctor of Philosophy	Doctorate	Full Time	Dr Adel Aref
2016 - 2020	Principal Supervisor	Understanding the Role of Androgen Receptor Signalling in Prostate Cancer: A Lipidomics Approach by MALDI Mass Spectrometry Imaging	Doctor of Philosophy	Doctorate	Full Time	Mr Shadrack Mulinge Mutuku
2013 - 2016	Principal Supervisor	Elucidating the Molecular Action of Synthetic Heat Shock Protein 90 Inhibitors in Prostate Cancer	Doctor of Philosophy	Doctorate	Full Time	Miss Heather Krista Armstrong
2013 - 2016	Co-Supervisor	The Role of microRNA-194 and microRNA-375 in Prostate Cancer Metastasis	Doctor of Philosophy	Doctorate	Full Time	Dr Rajdeep Das
2008 - 2011	Co-Supervisor	Investigating Lymphatic Vascular Remodelling During Postnatal Mouse Mammary Gland Morphogenesis	Doctor of Philosophy	Doctorate	Full Time	Ms Kelly Louise Betterman
2007 - 2015	Principal Supervisor	Combinatorial Targeting of the Androgen Receptor for Prostate Cancer Therapy	Doctor of Philosophy	Doctorate	Full Time	Miss Sarah Carter
2006 - 2010	Co-Supervisor	The Role of Epigenetic Modifications in Prostate Tumourigenesis	Doctor of Philosophy	Doctorate	Full Time	Ms Karen Huiqin Chiam
2004 - 2008	Co-Supervisor	Characterisation of a Dominant Negative Androgen Receptor in Prostate Cancer Cells	Doctor of Philosophy	Doctorate	Part Time	Dr Margaret Centenera
2004 - 2008	Principal Supervisor	Androgen Signalling in Normal and Malignant Breast Epithelial Cells	Doctor of Philosophy	Doctorate	Part Time	Ms Amelia Peters
2003 - 2007	Co-Supervisor	Targeting the Androgen Receptor as a Therapeutic Strategy for Prostate Cancer	Doctor of Philosophy	Doctorate	Full Time	Miss Deborah Marrocco

Other Supervision Activities

Date	Role	Research Topic	Location	Program	Supervision Type	Student Load	Student Name
2020 - ongoing	Co-Supervisor	A comprehensive assessment of cancer cell metabolism	University of Sydney	-	Doctorate	-	Nancy Santiappillai

Committee Memberships

Date	Role	Committee	Institution	Country
2021 - ongoing	Chair	Australian Prostate Cancer BioResource Executive Committee	Australian Prostate Cancer BioResource	Australia
2021 - ongoing	Chair	Research Committee	Prostate Cancer Foundation of Australia	Australia
2021 - ongoing	Board Member	National Board of Directors	Prostate Cancer Foundation of Australia	Australia
2020 - ongoing	Member	ANZUP Cancer Trials Group, Scientific Advisory Committee	Australian and New Zealand Urogenital and Prostate (ANZUP)	Australia
2018 - ongoing	Chair	BROCADE Tissue Access Committee Chair	National Breast Cancer Foundation	Australia
2017 - ongoing	Member	Research Advisory Committee	Prostate Cancer Foundation of Australia	Australia
2016 - ongoing	Member	Faculty of Health Sciences Research Committee	The University of Adelaide	Australia
2016 - ongoing	Member	Genomics Executive Committee	South Australian Health and Medical Research Institute	Australia
2015 - ongoing	Member	Appointments Committee	South Australian Health and Medical Research Institute	Australia
2014 - 2015	Chair	School of Medicine Research Committee	The University of Adelaide	Australia
2013 - ongoing	Member	ANZUP Cancer Trials Group, Prostate and Translational Sub-Committee	Australian and New Zealand Urogenital and Prostate (ANZUP)	Australia
2012 - ongoing	Convener	Australian Prostate Cancer BioResource Executive Committee, Adelaide Node Coordinator	Australian Prostate Cancer BioResource	Australia
2012 - ongoing	Member	Australian Prostate Cancer Research - Scientific Member	Australian Prostate Cancer Research	Australia
2012 - 2015	Member	NHMRC Postdoctoral Reference Group	National Health and Medical Research Council	Australia
2012 - ongoing	Member	NHMRC Research Translation Faculty	National Health and Medical Research Council	Australia
2011 - ongoing	Member	Freemasons Foundation Centre for Men's Health Executive Committee	The University of Adelaide	Australia
2011 - ongoing	Member	Movember Global Action Plan for Prostate Cancer - Functional Group Leader	Movember	Australia
2009 - ongoing	Member	Postgraduate Coordinator, Adelaide Medical School	The University of Adelaide	Australia
2009 - ongoing	Member	Australian Prostate Cancer BioResource Executive Committee	Australian Prostate Cancer BioResource	Australia
2007 - 2009	Member	Institutional Biosafety Committee	Institute of Medical and Veterinary Science	Australia
2006 - 2013	Member	School of Medicine Research Committee	The University of Adelaide	Australia
2004 - 2009	Member	Institutional Biosafety Committee	The University of Adelaide	Australia
2003 - 2010	Member	South Australian Breast Cancer Study Group Executive	South Australian Breast Cancer Study Group	Australia
2003 - 2005	Board Member	Australian Society for Medical Research	Australian Society for Medical Research	Australia

Memberships

Date	Role	Membership	Country
2020 - ongoing	Member	Society for Basic Urological Research	United States
2012 - ongoing	Member	Australian & New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group	Australia
2011 - ongoing	Member	Centre for Personalised Cancer Medicine - University of Adelaide	Australia
2006 - ongoing	Member	Hanson Institute	Australia
2006 - ongoing	Member	Endocrine Society	United States
2006 - ongoing	Member	Endocrine Society of Australia	Australia
2004 - ongoing	Member	South Australian In Vivo Mouse Models Network	Australia
2001 - ongoing	Member	Australian Prostate Cancer Collaboration	Australia
1999 - ongoing	Member	American Association for Cancer Research	United States
1995 - ongoing	Member	Australian Society for Medical Research	Australia

Community Engagement

Date	Title	Engagement Type	Institution	Country
2020 - ongoing	Updates in prostate cancer research	Public Community Engagement	Mount Barker Prostate Cancer Support Group	Australia
2020 - ongoing	Overloading fats in prostate cancer cells is key to destroying them say researchers	Public Community Engagement	The Senior (online publication)	Australia
2020 - ongoing	Radio interview	Public Community Engagement	5AA Adelaide	Australia
2020 - ongoing	Fat can kill cancer cells	Public Community Engagement	The Adelaide Advertiser (newspaper)	Australia
2020 - ongoing	Researcher Showcase Discussion Panel (Public Event)	Public Community Engagement	Cancer Council SA	Australia
2019 - ongoing	Working Together to Combat a Killer	Public Community Engagement	The Adelaide Advertiser (newspaper)	Australia
2018 - ongoing	Taking the Fight to Cancer	Public Community Engagement	The Adelaide Advertiser (newspaper)	-
2018 - ongoing	Defining Future Cancer Treatments, promotional video	Public Community Engagement	The University of Adelaide	Australia
2017 - ongoing	Lipids, obesity and prostate cancer	Public Community Engagement	Wealth and Wellbeing SAHMRI initiative launch for Bell Potter Securities	Australia
2017 - ongoing	Improving diagnosis, treatment and molecular imaging of prostate cancer	Public Community Engagement	SAHMRI Public Lecture Series - Cancer: Prevention, Diagnosis and Treatment (Public Event)	Australia
2017 - ongoing	New diagnosis and treatment tools for prostate cancer	Public Community Engagement	Lions Club Annual Meeting, Adelaide	Australia
2017 - ongoing	Networking advice for junior scientists	Scientific Community Engagement	Australian Society for Medical Research, Networking Event	Australia
2016 - ongoing	New markers for diagnosing prostate cancer	Public Community Engagement	Prostate Cancer Foundation of Australia Community Conversations (Public Event)	Australia
2015 - ongoing	Radio interview	Public Community Engagement	5AA Adelaide	-
2015 - ongoing	Radio interview	Public Community Engagement	ABC Radio Adelaide	Australia
2015 - ongoing	Lipids, obesity and prostate cancer	Public Community Engagement	North Shore Prostate Cancer Support Group	Australia
2015 - ongoing	Prostate hope in pioneer test	Public Community Engagement	The Adelaide Advertiser (newspaper)	Australia
2015 - ongoing	Working overseas to build your CV and future career	Scientific Community Engagement	Australian Society for Medical Research, Networking Event	Australia
2015 - ongoing	World-first Cancer Research	Public Community Engagement	The Adelaide Review (newspaper)	Australia
2015 - ongoing	Radio interview	Public Community Engagement	ABC Adelaide radio	Australia
2015 - ongoing	Associate Professor Lisa Butler assembles world class team in bid to develop new biomarkers	Public Community Engagement	Prostate News (magazine)	Australia
2014 - ongoing	International research team formed to make impact on clinical care for prostate cancer patients	Public Community Engagement	The Lead SA (online newspaper)	Australia
2014 - ongoing	Prostate Team’s $3m Aim	Public Community Engagement	The Adelaide Advertiser (newspaper)	Australia
2014 - ongoing	Radio interview	Public Community Engagement	ABC Radio Adelaide	Australia
2014 - ongoing	Challenges in prostate cancer research (lay presentation)	Public Community Engagement	Royal Adelaide Hospital	Australia
2014 - ongoing	Public laboratory tours	Public Community Engagement	South Australian Health and Medical Research Institute	Australia
2014 - ongoing	Regular Consumer Advisory Group Meetings	Public Community Engagement	The University of Adelaide	Australia
2012 - ongoing	Radio interview	Public Community Engagement	5AA Adelaide	Australia
2012 - ongoing	Challenges in prostate cancer research - Research Tuesday Public Lecture Series	Public Community Engagement	The University of Adelaide	Australia
2012 - ongoing	Towards improved management of breast and prostate cancer	Public Community Engagement	Cancer Care EXPO (Public Event)	Australia
2011 - ongoing	Probing the causes and treatment of prostate cancer	Public Community Engagement	Toshiba Medical presentation to radiology professionals	Australia
2008 - ongoing	Television news story	Public Community Engagement	Channel 9 Adelaide	Australia

Editorial Boards

Date	Role	Editorial Board Name	Institution	Country
2022 - ongoing	Editor	Molecular Cancer Research	American Association for Cancer Research	United States
2020 - ongoing	Associate Editor	Frontiers in Endocrinology - Systems Endocrinology	Frontiers in Endocrinology	United States
2019 - ongoing	Board Member	Journal of the National Cancer Institute	Journal of the National Cancer Institute	United States
2015 - ongoing	Board Member	Frontiers in Endocrinology	Frontiers in Endocrinology	United States
2015 - ongoing	Board Member	Frontiers in Oncology	Frontiers in Oncology	United States

Review, Assessment, Editorial and Advice

Date	Title	Type	Institution	Country
2021 - ongoing	Grant Review	Grant Assessment	European Science Foundation	-
2020 - ongoing	Grant Review	Grant Assessment	Swiss National Science Foundation	Switzerland
2019 - ongoing	Grant Review	Grant Assessment	Australia-India Strategic Research Fund	Australia
2018 - ongoing	Grant Review	Grant Assessment	ANZUP Below the Belt Fund	Australia
2017 - ongoing	Grant Review	Grant Assessment	Cancer Institute of NSW	Australia
2017 - ongoing	Grant Review	Grant Assessment	Prostate Cancer UK	United Kingdom
2015 - ongoing	Grant Review Panel	Grant Assessment	Health Research Council of New Zealand	New Zealand
2015 - ongoing	Research Advisory Committee	Grant Assessment	Prostate Cancer Foundation of Australia	Australia
2015 - ongoing	Grant Review	Grant Assessment	Cure Cancer Australia	Australia
2015 - ongoing	Grant Review	Grant Assessment	Cancer Research UK	United Kingdom
2013 - ongoing	Early Career Fellowships Review Panel	Grant Assessment	National Breast Cancer Foundation	Australia
2012 - ongoing	Grant Review	Grant Assessment	Cancer Council	Australia
2012 - ongoing	Grant Review	Grant Assessment	Prostate Cancer Foundation of Australia	Australia
2012 - ongoing	Grant Review	Grant Assessment	National Breast Cancer Foundation	Australia
2011 - ongoing	Grant Review Panel	Grant Assessment	Cancer Australia	Australia
2010 - ongoing	Oncology Grant Review Panels	Grant Assessment	National Health and Medical Research Council	Australia
2005 - ongoing	Grant Review	Grant Assessment	National Health and Medical Research Council	Australia

Position: Lead SAiGENCI Associate
Phone: 0881284360
Email: lisa.butler@adelaide.edu.au
Campus: North Terrace
Building: SAHMRI - Prostate Cancer Research Group, floor 5
Org Unit: South Australian Immunogenomics Cancer Institute